Oct 08th 2013 - Edison Investment Research today published a report on ArQule entitled "Breathing New Life Into Tivantinib". In summary, the report says:
Confirmation that tivantinib offers a statistically significant benefit in terms of progression-free and overall survival in high c-MET, NSCLC has brought renewed hope that the drug may have utility in this subset of patients. In this note, we provide an analysis of the new data and consider the likelihood that a new NSCLC trial could be started by ArQule’s partner, Daiichi Sankyo. We have reduced the success rate of the HCC trial, hence the valuation due to the IDMC’s recommendation of dose modification.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »